We aimed to systematically identify genetic modifiers that regulate the response of EGFR-mutant NSCLC cells to EGFR TKI treatment by applying a genome-scale CRISPR-Cas9 loss-of-function screening approach (Figure 1D). Here, EGFR is linked to non-small cell lung carcinoma.